October 28, 2020 — Helius Medical Technologies (Canada), subsidiary of Helius Medical Technologies, Inc, a neurotech company focused on neurological wellness and BrainFx, a leading digital neurofunctional assessment platform are teaming up to educate neurorehabilitation clinics about advancements in how brain disorders and neurological dysfunction are assessed and treated in Canada.
Neurological conditions such as Multiple Sclerosis (MS) and Traumatic Brain Injuries (TBI) are a growing challenge for Canadians. New assessments and new treatment options are burgeoning areas of scientific investigation as healthcare professionals strive to reduce the incidence and impact of these disorders. Helius Canada and BrainFx have committed to understanding and advancing the science of assessment and treatment of MS and TBI by combining evidence-based clinical research with real-world application to help Canadian patients today and in the future.
Initially through this collaboration, Helius Canada and BrainFx will share the science behind their individual, state-of-the-art platforms to raise awareness of brain health in Canada and educate the neurotherapy community on the benefits of their technology and advancements in clinical research. Moving forward, there is a strong desire from both organizations to raise awareness regarding the use of their technologies in real-world applications, which offers the potential to further understand the patient experience and to open new pathways for clinical investigation.
To learn more about the PoNS™ device by Helius, visit http://www.ponstreatment.ca/
For more information on BrainFx, visit http://18.104.22.168/.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS™). For more information, visit www.ponstreatment.ca or www.heliusmedical.com
About the PoNS™ Device and PoNS Treatment™
The Portable Neuromodulation Stimulator (PoNS™) is an authorized class II, non-implantable medical device in Canada intended for use as a short-term treatment (14 weeks) for gait deficit due to mild and moderate symptoms from MS and for chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy. The PoNS™ is an investigational medical device in the United States, the European Union (“EU”), and Australia (“AUS”). The device is currently under review for de novo classification and clearance by the FDA. It is also under premarket review by the AUS Therapeutic Goods Administration. PoNS Treatment™ is currently not commercially available in the United States, the European Union or Australia.
BrainFx develops digital, neurofunctional assessments tools to detect the milder forms of cognitive dysfunction that other tests can miss. BrainFx’s mission is to improve the quality of life of those living with brain disorders globally by making the invisible effects of brain disorders visible. By combining research with technology and clinical knowledge, BrainFx assessments deliver unique insights to health care teams across the continuum of care and help answer ‘What Next?’ to make a difference in health outcomes. For more information, visit www.brainfx.com
About the BrainFx Platform
BrainFx delivers clinically useful online and tablet based clinical assessment tools. BrainFx Assessments are specifically designed to measure the functional impact of early or mild to moderate brain disorders of all types. Assessments assist health providers in efficiently building a comprehensive neurofunctional profile of a patient that includes cognitive and sensory skills, mood, behaviour, sleep, nutrition, activities of daily life, quality of life, and more for setting a baseline or developing targeted treatment plans that can be tracked over time. The BrainFx Assessment Suite includes three assessments:
- The quick and simple BrainFx SCREEN (10-15 minutes)
- The comprehensive and multi-sensory BrainFx 360 (90-minutes)
- (New) The completely virtual or contactless BrainFx Virtual Cognitive Assessment (30-minutes)
BrainFx Assessments are authorized by Health Canada as a Class 1 Software as a Medical Device. BrainFx Assessments statements have not been evaluated by any other regulatory bodies.